CSF1R and tenosynovial giant cell tumor, diffuse type: As mentioned in the NCCN Soft Tissue Sarcoma Guidelines, this finding supports the use of CSF1R inhibitors, most notably pexidartinib for symptomatic, unresectable, or relapsing TGCT/PVNS, highlighting the importance of a molecularly driven therapeutic approach [64].